(212) Topical Lidocaine Patch Produces a Significant Improvement in Quality of Life Indicators in Treated PHN Patients: Results of a Multicenter Open-Label Trial

Abstract

Aim: To assess quality of life (QOL) treatment effects on postherpetic neuralgia (PHN) patients treated with lidocaine patch 5% (Lidoderm®). Methods: An open-label, non-randomized, multi-center study evaluated the efficacy of lidocaine patch 5% using quality of life indicators over a 28 day treatment period in 333 subjects with postherpetic neuralgia (PHN). A maximum of 3 patches was applied to cover the area of greatest pain during a 12-hour period each day for 28 days. The Brief Pain Inventory (BPI- Short Form) was completed at baseline, day 7, day 14 and day 28. Patients reported distinct aspects of QOL using a 0 (does not interfere) to 10 (completely interferes) categorical scale. Results: Lidocaine patch 5% significantly (p = 0.0001) reduced the impact of pain on all quality of life indicators at all time points [Table 1; Figure 1]. Conclusion: This large multi-center study further demonstrates that lidocaine patch 5% produces a significantly positive impact on all measured quality of life indicators in the 333 PHN patients studied. The support of Endo Pharmaceuticals Inc. for this research project is gratefully acknowledged. Table 1. Change in Impact of Pain on Quality Of Life Indicators (N = 333) Baseline to Day 7 Baseline to Day 14 Baseline to Final Mean Change SD Pvalue Mean Change SD Pvalue Mean Change SD Pvalue General Activity 1.6 3.6 0.0001 2.1 3.0 0.0001 2.1 3.3 0.0001 Mood 2.0 3.1 0.0001 2.4 3.1 0.0001 2.3 3.3 0.0001 Walk 1.1 2.8 0.0001 1.4 3.0 0.0001 1.3 3.0 0.0001 Work 1.7 2.7 0.0001 1.8 3.0 0.0001 2.0 3.2 0.0001 Relationships w/Others 1.5 2.9 0.0001 1.7 3.2 0.0001 1.8 3.3 0.0001 Sleep 1.7 3.1 0.0001 1.9 3.2 0.0001 2.0 3.4 0.0001 Enjoy Life 1.8 3.1 0.0001 2.2 3.0 0.0001 2.3 3.2 0.0001